Recro Gainesville has added a 24,000-sq.-ft. facility, which includes high-potent material processing space, near its existing 97,000- sq.-ft. contract development and manufacturing plant. The company is a wholly owned subsidiary of Recro Pharma, Inc., and a provider of pharmaceutical solid oral dose development and manufacturing services.   The expanded capabilities will allow Recro Gainesville to provide a broader range of services from formulation and development through clinical trial mate...